Alergan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alergan

Quick Facts

Property Description
Active Ingredient Loratadine
Form Tablet, Syrup
Pharmacological Class Second-Generation Antihistamine
General Purpose Systemic relief from allergic symptoms
Origin Synthetic Compound

What Type of Medicine is Alergan (Loratadine)?

Alergan is a medicinal preparation whose active ingredient is Loratadine, classifying it as a second-generation antihistamine. This chemical designation confirms its role in counteracting the effects of the natural chemical histamine in the body, which drives allergic symptoms. Loratadine is a synthetic compound chemically categorized as a piperidine derivative. Its molecular structure is a distinctive feature, as it limits penetration into the central nervous system, making it typically non-sedating when compared to older agents in its class. This non-sedating profile has been clinically recognized through numerous pharmacological studies comparing it to placebo and first-generation compounds.


Composition and Available Forms of Alergan

Alergan is a single-active-ingredient product focused exclusively on Loratadine. This medicine is intended for oral intake, meaning the compound is absorbed systemically after swallowing. The drug is supplied in two principal dosage forms: a solid tablet and a liquid syrup, often marketed for both adults and pediatric patients. While Loratadine itself is the compound consumed, it functions as a precursor that the body metabolizes into its main therapeutic agent, Desloratadine, which continues the pharmacological effect.


General Purpose and Core Benefit

The general purpose of this medicine is to interrupt the biological signaling associated with an allergic reaction by acting as a peripheral H1-receptor antagonist. In an allergic event, the body releases histamine, which binds to H1 receptors and causes inflammation and irritation. Loratadine selectively blocks the H1 receptor, preventing histamine from initiating these responses. This selective H1-blockade is the fundamental mechanism that provides systemic relief from the physiological effects driven by histamine in general allergic conditions, such as when managing a typical scenario involving skin or respiratory allergic symptoms.

What side effects are possible with Alergan?

Possible Side Effects and Safety Information

The officially documented safety profile of Alergan (Loratadine) is structured according to regulatory classifications, detailing reported adverse reactions by both frequency and the physiological systems affected.


Frequency-Classified Adverse Reactions

Adverse reactions are classified according to regulatory standards (e.g., EMA/ICH frequency bands):

Classification Examples of Adverse Reactions (by Regulatory Terminology)
Common Headache, Somnolence (Drowsiness), Fatigue.
Uncommon Increased Appetite, Insomnia.
Very Rare Dizziness, Convulsion, Nausea, Dry mouth, Gastritis, Palpitation, Tachycardia, Abnormal hepatic function, Hypersensitivity reactions (including angioedema and anaphylaxis), Rash, Alopecia.
Not Known Weight increased.

System-Organ-Class Groupings

Regulatory documents group side effects into specific physiological categories, including Nervous System Disorders (e.g., Convulsion, Headache), Cardiac Disorders (e.g., Tachycardia, Palpitation), Gastrointestinal Disorders (e.g., Gastritis, Nausea), and Immune System Disorders (e.g., Hypersensitivity reactions).


Serious Safety Considerations

The label explicitly notes certain adverse events as Very Rare but serious, such as Hypersensitivity Reactions (including angioedema and anaphylaxis), Abnormal Hepatic Function, and Convulsion. Regarding long-term use, the official profile notes no clinically significant changes were observed in vital signs or ECGs during extended treatment.

--žu### Population-Specific Safety Notes

  • Severe Hepatic Impairment: Loratadine is administered with caution in individuals with severe liver impairment, as the clearance of the drug may be reduced, necessitating dose modification.
  • Pediatric Population (2–12 years): In clinical trials, common adverse reactions reported in this age group in excess of placebo included Headache, Nervousness, and Fatigue.
  • Breastfeeding: Loratadine is excreted into breast milk, and its use during lactation is generally not recommended by regulatory agencies.

Safety Restrictions

The medicine is contraindicated in patients with known hypersensitivity to Loratadine or any of its components. Additionally, the label requires that the medicine be discontinued at least 48 hours prior to skin allergy testing, as the antihistamine effect may suppress the results.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Alergan (Loratadine) describes specific clinical manifestations and mandates immediate emergency action. In the event of a suspected overdosage, regulatory documents require individuals to seek immediate medical attention or contact a Poison Control Center right away.


Documented Overdose Presentations

Element Regulatory Statement on Overdose
Documented Manifestations Symptoms reported include somnolence (drowsiness), headache, and tachycardia (fast heart rate). Overdosage may also be associated with an increased occurrence of anticholinergic symptoms.
At-Risk Populations An increased incidence of somnolence at doses higher than recommended is noted in the elderly and in patients with hepatic or renal impairment.

Management following immediate action is symptomatic and supportive. No specific antidote for Loratadine is known. Medical monitoring of the patient must be continued after initial emergency treatment. Procedures such as the administration of activated charcoal as a slurry or gastric lavage may be considered to reduce absorption, depending on the clinical context. Regulatory information also states that the substance is not effectively removed by haemodialysis.


Connection to the Overall Overdose Profile

Regulatory documents define the overdose profile by specifically listing the expected central nervous system and cardiovascular manifestations. This presentation triggers explicit emergency actions, which require immediate medical attention. The official information further structures the necessary response by stating that management must be symptomatic and supportive, emphasizing the absence of a specific antidote and the requirement for post-emergency patient monitoring.

Therapeutic Uses of Alergan

What Alergan Treats: Main Uses and Benefits

Alergan (Loratadine) is commonly used in situations involving certain distressing symptoms associated with the body's allergic response. It may assist with symptom clusters that appear suddenly or fluctuate, providing support that helps ease the overall symptom burden during periods of heightened symptoms. Loratadine is indicated for the temporary relief of key allergy manifestations.

The medication is considered relevant for managing symptoms that interfere with daily comfort. It is applicable for easing symptoms associated with seasonal allergic rhinitis (hay fever), perennial allergic rhinitis, and chronic idiopathic urticaria (hives). The medication is commonly used when short-term symptomatic assistance is needed for manifestations like persistent sneezing, runny nose, itching of the nose and throat, watering of the eyes, and pruritus (itching) from hives. It may assist with maintaining functional stability when symptoms interfere with routine activities.


Quick Facts: Management of Allergic Symptoms

Property Description
Primary Focus Upper airway, ocular, and cutaneous (skin) symptoms.
Typical Context Seasonal flare-ups and chronic, recurrent manifestations.
Contextual Benefit Supportive symptom management.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Alergan — Official Regulatory Information

Official regulatory documents define strict population eligibility for Loratadine (Alergan) based on age, physiological status, and underlying health conditions.

Classification Eligibility Status (as stated in label)
Populations for whom use is allowed Adults and adolescents ge 12 years. Children ge 2 years (liquid formulation) and ge 6 years (tablets) under standard conditions.
Populations for whom use is contraindicated Patients with known hypersensitivity (allergy) to loratadine or to any excipients in the formulation.
Age-related eligibility rules Children under 2 years of age have safety and efficacy not established. Older adults may require special caution due to potential changes in renal clearance.
Condition-specific eligibility rules Use requires caution and dose adjustment for patients with severe hepatic impairment or severe renal impairment (GFR <30 mL/minute), as stated in labeling.
Pregnancy and lactation eligibility status Use during pregnancy and by breastfeeding women is not recommended; the drug is excreted into breast milk.

Eligibility-related restrictions

Certain formulations are restricted for patients with metabolic disorders: tablet formulations containing lactose are contraindicated for those with rare hereditary problems of galactose intolerance. Use must also be discontinued at least 48 hours prior to skin allergy testing.

Connection to the overall eligibility profile

Regulatory documents establish an absolute contraindication based on allergy and define conditional use requirements for compromised populations, such as those with severe liver or kidney disease. These classifications determine the specific groups that may or may not use the medicine safely under standard labeled conditions.

What should I know about interactions with other medicines?

Alergan may interact with other medicines, requiring careful consideration of concomitant therapy. These interactions primarily involve agents that influence the central nervous system or affect blood pressure and circulating amines.

Product Category Interaction Classification Potential Effect/Mechanism
MAO Inhibitors Contraindicated Risk of hypertensive crisis or other serious reactions due to effects on systemic circulating amines.
Antidepressants Contraindicated Specifically, tricyclic antidepressants and mianserin (which affect noradrenergic transmission) should be avoided due to the potential for blunting Alergan's effects.
CNS Depressants Use with Caution An additive or potentiating effect is possible when combined with substances such as alcohol, barbiturates, opiates, sedatives, or general anaesthetics, increasing the risk of drowsiness or sedation.
Antihypertensives Use with Caution Concomitant use with antihypertensives or cardiac glycosides is advised with caution, as Alergan itself may cause a clinically significant reduction in blood pressure.
Metabolism-Affecting Agents Use with Caution Medications that affect the metabolism and uptake of circulating amines (e.g., chlorpromazine, methylphenidate, reserpine) should be used cautiously.

For patients using more than one topical ophthalmic product, the products must be administered at least five minutes apart to ensure proper drug absorption and limit potential wash-out effects.

Mechanism of Action

H1 Receptor Inverse Agonism: Interruption of the Gq Cascade

The core pharmacological action is executed by the active metabolite, Desloratadine, which operates as a highly selective inverse agonist at the peripheral Histamine H1 receptor. By stabilizing the H1 receptor in its inactive conformation, the molecule prevents histamine from inducing activation of the Gq-protein signaling pathway. This mechanistic interruption prevents the subsequent signaling cascades responsible for promoting vascular permeability and inducing smooth muscle contraction.


Peripheral Specificity and Prodrug Activation

The mechanism is restricted primarily to the periphery due to the molecule’s chemical properties, which limit its ability to cross the blood-brain barrier (BBB), resulting in negligible engagement of Central Nervous System (CNS) receptors. The administered Loratadine acts as a prodrug, undergoing rapid metabolism into the active molecule, Desloratadine. This transformation generates a continuous presence of the active molecule capable of persistent receptor blockade.


Non- H1 Inflammatory Modulation

Beyond the core receptor blockade, the active metabolite modulates specific inflammatory processes by inhibiting the release of certain chemical mediators from cells such as mast cells and basophils. This complementary action dampens the signaling cascade by reducing the quantity of released mediators. This provides complementary modulation of local tissue responses to mediators distinct from histamine.

Dosage and Administration Information

How to Use Alergan: Official Administration Guidelines

Alergan (Loratadine) is administered exclusively via the oral route across its available forms, including tablets, syrup, and orally disintegrating tablets. The official usage pattern dictates a once-daily schedule, as a single dose is intended to provide antihistaminic activity lasting in excess of 24 hours. The medicine may be taken with or without food.


Official Dosing and Procedural Rules

Administration Scope Detail
Route of administration Exclusively oral administration.
Dosing schedule Standard Dose (Adults & Children 6 years): 10 mg once daily. Severe Impairment Adjustment: 10 mg every other day for patients 6 years with severe renal or hepatic impairment.
Timing in relation to meals May be taken with or without food.
Preparation requirements Oral Solution/Syrup must be measured using a calibrated device provided with the product. Orally Disintegrating Tablets are placed on the tongue to dissolve and are then swallowed.
Age-group administration rules Children 6 years and older: 10 mg once daily. Children 2 to under 6 years: 5 mg once daily.
Missed-dose rules If a dose is missed, it should be taken when remembered, but if it is almost time for the next scheduled dose, the missed dose is skipped entirely. Do not take a double dose.

Connection to the Overall Use Protocol

This official protocol establishes a structured, non-divisible once-daily oral schedule as the primary method for using the medicine. The standard administration is designed for simplicity, providing flexibility regarding meals, but defines clear maximum daily limits and mandates specific dosing adjustments for patients with severe liver or kidney impairment. Adherence to these limits and procedural instructions ensures the correct administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Alergan (Loratadine)


Evidence for Use in Seasonal and Perennial Allergic Rhinitis

Research involving Loratadine was studied for hay fever symptoms and primarily involves numerous short-term Randomized Controlled Trials (RCTs) and subsequent analyses that pool the data from these studies. This evidence contributes to the regulatory review for this designation. Studies conducted during periods of increased symptom activity explored how symptoms change over time. Research examined standardized measurement scales, such as Total Symptom Scores, which aggregate patient-reported outcomes describing symptoms like sneezing, running nose, and ocular irritation.

In these controlled settings, trials reported systematic measurements comparing symptom scores following Loratadine administration versus those observed with placebo. Studies described patterns where the medicine was monitored over a 24-hour period following a single dose. Findings describe patterns observed in the studies that provided data for regulatory assessment in this context.

Evidence for Use in Chronic Idiopathic Urticaria (Hives)

Loratadine was also studied for Chronic Idiopathic Urticaria (hives), which is characterized by fluctuating manifestations. Evidence is derived primarily from controlled trials that focused on conditions involving periods of heightened symptoms. Research examined outcomes related to physical discomfort, monitoring both the intensity of the itching (pruritus) and the number of wheals present. The systematic reviews and meta-analyses documented that the body of research data was utilized for regulatory assessment in this condition.

Evidence in Special Populations and Research Uncertainty

The research has explored how Loratadine was evaluated in specific populations where metabolism or clearance may differ. Studies monitored individuals with renal or hepatic impairment, and observed patterns where drug concentration levels appeared elevated in these patient groups compared to younger, healthy adults. Loratadine was also studied for use in pediatric populations, including children as young as 2 years old for allergic rhinitis. However, regulatory authorities noted that data for certain groups, such as children under the age of 2 years for allergic rhinitis, remain insufficient for use designation.

Long-term effects are not fully established because follow-up durations were limited in the primary clinical trials. Comparative evidence is lacking against every available treatment, and some subgroup findings are uncertain due to variability across individual studies, meaning research is ongoing to fully contextualize the medicine.

Key Studies & References

  1. Loratadine Drug Information: National Library of Medicine (NIH)

Frequently Asked Questions (FAQ)

Common questions about Alergan (FAQ)


Q: Does Alergan have a generic version available?

A: Yes, Alergan contains the active ingredient Loratadine, which is widely available as a generic drug. Regulatory authorities have approved various generic versions after reviewing data that confirmed their therapeutic equivalence to the original product.

Q: Are there different strengths of Alergan?

A: Official product information describes different strengths depending on the formulation, such as a 10 mg tablet and a 5 mg per 5 mL strength for the liquid syrup. The specific concentrations available align with the dosing instructions established for different age groups in the official label.

Q: Does Alergan cause weight gain or loss?

A: Official safety documents list 'Weight increased' under the frequency classification of 'Not Known.' This designation means that the available data from studies are not sufficient to estimate how often this effect might occur. The available clinical data do not allow for the estimation of the frequency of weight changes as a side effect.

Q: Are the side effects of Alergan long-lasting?

A: The medicine is designed for once-daily use, providing effects for over 24 hours. The active molecule has a reported average elimination half-life of approximately 28 hours in healthy adults. Based on this pharmacokinetic profile, the effects, including any associated side effects, are generally expected to be short-term.

Q: How quickly does Alergan start working after the first use?

A: Studies on the drug’s effects show that antihistaminic activity has been measured beginning within 1 to 3 hours after the first oral dose. The effect typically reaches its highest point around 8 to 12 hours after administration.

Q: Do I need to take Alergan every day, or only when I have symptoms?

A: The medicine is administered on a structured once-daily schedule to maintain continuous antihistamine activity for more than 24 hours. The determination of continuous versus intermittent use is based on the condition being addressed and the established administration pattern.

Q: Does Alergan affect blood pressure or heart rate?

A: Official documents note that effects on the heart, such as fast heart rate (Tachycardia) or Palpitations, are possible but are classified as very rare adverse reactions. A reduction in blood pressure has been noted in the context of co-administering with certain other medications.

Q: What happens if I forget to take Alergan?

A: Official regulatory guidance states that if a dose is missed, it should be taken when remembered. If it is nearly time for the next scheduled dose, the missed dose is recommended to be skipped entirely. Official documentation states that a double dose should not be taken to compensate for a missed dose.

Q: How long does it takes for Alergan to leave your system?

A: The clearance time is measured by the elimination half-lives of the parent drug and its active metabolite. In healthy adults, the parent drug (Loratadine) has a mean half-life of about 8.4 hours, while the active metabolite (Desloratadine) has a mean half-life of approximately 28 hours.

Q: Can Alergan be taken with common over-the-counter pain relievers?

A: Regulatory documents list specific categories of interacting medications, such as CNS depressants. No notable interactions have been reported in studies with common non-prescription pain relievers such as acetaminophen or ibuprofen.

Q: Is Alergan appropriate for people with kidney problems?

A: Use in individuals with severe renal impairment (kidney disease) is addressed by special administration guidelines in the regulatory documents. Regulatory agencies define a modified administration schedule, such as 10 mg every other day, to accommodate reduced drug clearance in this population.

Q: Is Alergan a scheduled or controlled substance?

A: The active ingredient, Loratadine, is not classified or scheduled under the U.S. Federal Controlled Substances Act (CSA). It is not typically regulated as a controlled substance by major international authorities.

Q: Can Alergan be split or crushed?

A: Official instructions for the orally disintegrating tablet form state that it must dissolve on the tongue and not be split. For standard tablets, the ability to split or crush them is not typically addressed in the product information unless the tablet is scored.

Q: Can children or teenagers use Alergan?

A: Yes, Alergan is officially designated for use in specific pediatric groups. This includes children 6 years and older (tablets) and children 2 years and older (syrup/liquid), though regulatory approval for use in children under 2 years is not established.

Q: Is Alergan used for anxiety?

A: The official, approved purpose of Alergan (Loratadine) is to relieve symptoms of allergic rhinitis (hay fever) and chronic idiopathic urticaria (hives). It is not approved or intended for the treatment of anxiety or other mental health conditions.

Q: How long after stopping Alergan do the effects wear off?

A: The maximum antihistaminic effect has been observed to last in excess of 24 hours following a single dose. The therapeutic effects are expected to slowly decrease over the following days as the active metabolite is gradually eliminated from the body.

Q: Are there any known issues with fertility associated with Alergan use?

A: Preclinical data (animal studies) do not indicate direct or indirect harmful effects on fertility or reproductive capacity. Effects on offspring viability were observed in animal studies, but only at plasma levels that were significantly higher than those achieved during typical human use.

How should Alergan be stored and disposed of?

Regulatory documents define mandatory conditions for the storage and disposal of Loratadine (Alergan) to ensure product stability and safety.

Item Requirement
Temperature Tablets must be stored at controlled room temperature (20 C to 25 C). Syrup must be kept between 2 C and 25 C.
Protection Store in the original container, keep the container tightly closed, and protect the medicine from excessive moisture. The Syrup must not be frozen.
Stability Loratadine Syrup must be discarded if it becomes discolored.
Child Safety The medicine must be stored out of the sight and reach of children.
Disposal Unused or expired product should not be disposed of via wastewater or normal household waste. Official disposal methods include using a drug take-back program or following regulatory guidelines for household trash disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alergan found in:

A-Z Index: